ArticleJornal brasileiro de nefrologia
Survival in hemodialysis in Brazil according to the source of payment for the treatment: Public Healthcare System (SUS) versus private insurance.
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- Position statement of the Brazilian Society of Nephrology on the refusal and discontinuation of dialysis.Jornal brasileiro de nefrologiaGuideline
- Recommendations of the Brazilian Society of Nephrology for hemodiafiltration in maintenance dialysis therapy.Jornal brasileiro de nefrologiaGuideline
- Registry of access to chronic dialysis initiation at the Public Health System in Brazil.International urology and nephrology · 2026Article
- Maintenance of inequity in the provision of chronic dialysis treatment in Brazil.Jornal brasileiro de nefrologia · 2026Article
- BRIGHT-HD-A Brazilian Research Investigation on Public Health Gains Comparing Survival Rates Between Hemodialysis and Hemodiafiltration: An Observational Study.Journal of clinical medicine · 2025Article
- A Decade of Change in Peritoneal Dialysis in Brazil: Challenges and Perspectives in the Public Health System.Healthcare (Basel, Switzerland) · 2025Article
- Biopsychosocial Factors Associated with Activities of Daily Living Limitations in Chronic Kidney Disease Patients: Insights from the Brazilian Population.International journal of environmental research and public health · 2024Article
- Geographic inequities in hemodialysis access: a call to reassess dialysis facility locations in Brazil.Journal of nephrology · 2024Article
- Impact of Dialysis Time on Long-term Outcomes in HLA-identical Living Donor Kidney Transplant Recipients.Transplantation direct · 2024Article
- Sociodemographic and Economic Correlates of Dialysis Vintage in a Resource Challenged Setting: A Four-Year Prospective Study in Southwest Nigeria.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrazil has the largest public and universal healthcare system in the world, but little is known about the outcomes of patients on hemodialysis (HD) in the country according to the source of funding for the treatment.
objectiveTo compare the profile and survival of patients under HD treatment funded by the Public Healthcare System (SUS) to those with private insurance.
methodsRetrospective analysis of adults undergoing HD between 2012 and 2017 in 21 dialysis centers in Brazil that provided both by the SUS and private health insurance. Participants, regardless of the paying source, received similar dialysis treatment. Data were censored after 60 months of follow-up or at the end of 2019.
results4,945 patients were included, 59.7% of which were financed by the SUS. Patients financed by SUS, compared to those with private insurance, were younger (58 vs. 60 years; p < 0.0001) and with a lower prevalence of diabetes (35.8% vs. 40.9%; p < 0.0001). The 60-month survival rates in these groups were 51.1% and 52.1%, respectively (p = 0.85). In the analysis of the subdistribution proportional hazard ratio by the Fine-Gray model, including adjustment for concurrent outcomes, a significant increase in the risk ratio for death was found (1.22 [95% confidence interval 1.04 to 1.43]) in patients with treatment funded by the SUS.
conclusionsPatients on HD with treatment funded by the SUS have a higher adjusted risk of death when compared to those with private insurance, despite similar dialysis treatment. Factors not directly related to dialysis therapy could explain this difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.